U.S. markets open in 6 hours 13 minutes

Chimerix, Inc. (CMRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8100+0.1200 (+3.25%)
At close: 1:00PM EST
Full screen
Loading interactive chart...
  • Analysts Have Lowered Expectations For Chimerix, Inc. (NASDAQ:CMRX) After Its Latest Results
    Simply Wall St.

    Analysts Have Lowered Expectations For Chimerix, Inc. (NASDAQ:CMRX) After Its Latest Results

    Shareholders of Chimerix, Inc. (NASDAQ:CMRX) will be pleased this week, given that the stock price is up 15% to...

  • Revenue Downgrade: Here's What Analysts Forecast For Chimerix, Inc. (NASDAQ:CMRX)
    Simply Wall St.

    Revenue Downgrade: Here's What Analysts Forecast For Chimerix, Inc. (NASDAQ:CMRX)

    Market forces rained on the parade of Chimerix, Inc. (NASDAQ:CMRX) shareholders today, when the analysts downgraded...

  • Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
    GlobeNewswire

    Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference

    DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.About ChimerixChimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).DSTAT is a potential first-in-class glycosaminoglycan compound derived from porcine heparin that, compared to commercially available forms of heparin, may be dosed at higher levels without associated bleeding-related complications. DSTAT is being studied in a Phase 2/3 trial to assess safety and efficacy in adults with acute lung injury with underlying COVID-19. A Phase 3 trial protocol to study DSTAT in acute myeloid leukemia has been developed in alignment with the US Food and Drug Administration (FDA) and site activation is expected in early 2021. BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. For further information, please visit the Chimerix website, www.chimerix.com.CONTACT:Investor Relations:         Michelle LaSpaluto 919 972-7115 ir@chimerix.com Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com Media: David Schull Russo Partners 858-717-2310 David.Schull@russopartnersllc.com